Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced the appointment of Lisa Nolan, Ph.D., to the newly-created position of Chief Business Officer.  Dr. Nolan, who held similar positions at Relmada Therapeutics, Topigen Pharmaceuticals and SkyePharma, brings over two decades of experience in corporate strategy, M&A, funding partnerships, and out-licensing and in-licensing of development stage clinical assets.

“We are delighted to have Lisa join our leadership team given her impressive global experience in bioscience-focused corporate development,” said Peter D. Suzdak, Chief Executive Officer.  “Lisa’s extensive experience and strong track record completing significant licensing deals will be vitally important as we continue to advance Rexahn’s clinical programs and seek the optimal partnership structure for each of our programs.  I very much look forward to Lisa’s contributions and am pleased to welcome her to the Rexahn family.”

“It’s a pleasure to join Rexahn at such an important time in the Company’s evolution,” said Dr. Nolan. “I am excited to work closely with Peter and the leadership team to help Rexahn leverage its corporate development opportunities, and in so doing work to build increased value for shareholders.  I look forward to advancing partnership opportunities for Rexahn’s three novel, targeted oncology programs, which are progressing in clinical development.”

Dr. Nolan joins Rexahn from Relmada Therapeutics where she held the position of Chief Business Officer.  Prior to this, she was Managing Director of Nolex Advisors, LLC, where she led successful competitive processes for out-licensing of early and late-stage pharmaceutical products.  Over the course of her career, Dr. Nolan has held various leadership roles at biopharmaceutical companies including Chief Business Officer at Topigen Pharmaceuticals, where she championed and led the acquisition of Topigen by Pharmaxis.  Additionally, she served as Vice President, Global Business Development and Strategic Marketing for SkyePharma Inc., where she completed over a dozen out-licensing deals in the U.S. and Europe with deal values ranging in excess of $500 million.  Dr. Nolan holds a Ph.D. in clinical pharmacology and a M.Sc. and B.Sc. in pharmacy from Trinity College in Dublin, Ireland. (Original Source)

Shares of Rexahn are currently trading at $0.259 +0.001 (0.31%. RNN has a 1-year high of $0.66 and a 1-year low of $0.24. The stock’s 50-day moving average is $0.28 and its 200-day moving average is $0.32.

On the ratings front, FBR analyst Vernon Bernardino reiterated a Buy rating on RNN, with a price target of $3, in a report issued on May 19. The current price target implies an upside of 1100.0% from current levels. According to, Bernardino has a yearly average return of -18.3%, a 26.5% success rate, and is ranked #3931 out of 4035 analysts.

Rexahn Pharmaceuticals, Inc. is a development stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The company currently has three clinical stage oncology candidates, Archexin, RX-3117, and Supinoxin and a robust pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D gold and times.